BGMS Overview

Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.

Wall Street analysts forecast BGMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BGMS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bio Green Med Solution Inc revenue for the last quarter amounts to 778.00K USD, decreased

Bio Green Med Solution Inc. EPS for the last quarter amounts to -0.04 USD, decreased -81.82

Bio Green Med Solution Inc (BGMS) has 0 emplpoyees as of June 27 2026.

Today BGMS has the market capitalization of 3.32M USD.